Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice

Journal of Infectious Diseases

Volumn 176, Issue 2, 1997, Pages 331-338

  Keadle, Tammie L ^b   Laycock, Keith A ^b   Miller, Judith Kelvin ^b   Hook, Kelly K ^b   Fenoglio, E D ^b   Francotte, Myriam ^b   Slaoui, Moncef ^b   Michael Stuart, P ^b   Pepose, Jay S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; PROTEIN SUBUNIT; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; EYE INFECTION; HERPES SIMPLEX VIRUS 1; IMMUNOGENICITY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; ULTRAVIOLET B RADIATION; VACCINATION; VIRUS INFECTION;

EID: 0030743357     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514049     Document Type: Article

References (14)

1. Hermand P, Fabry L, Garcon N, et al. Effect of adjuvants on the immunogenicity of a recombinant herpes simplex virus glycoprotein D vaccine in primates [abstract 376]. In: Proceedings of the 17th International Herpes Workshop (Edinburgh). Edinburgh: Heriot-Watt University, 1992:376.
2. Hermand P, Fabry L, Garcon N, et al. Comparison of adjuvant efficacy of a recombinant herpes simples virus glycoprotein D subunit vaccine in the guinea pig model of HSV2 infection [abstract 388]. In: Proceedings of the 17th International Herpes Workshop, Edinburgh, 1992:388.
3. Francotte M, Pala P, Vanopstal O, et al. Comparative safety and immunogenicity of two adjuvant formulations of HSV2 glycoprotein D based subunit vaccines in man [abstract 38]. In: Proceedings of the 18th International HSV Workshop, Pittsburgh, 1993:38.
4. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharmacol Biotechnol 1995;6:495-524.
5. Laycock KA, Lee SF, Brady RH, Pepose JS. Characterization of a murine model of recurrent herpes simplex viral keratitis induced by ultraviolet B radiation. Invest Ophthalmol Vis Sci 1991;32:2741-6.
6. Miller JK, Laycock KA, Nash MM, Pepose J. Corneal langerhans cell dynamics after herpes simplex virus reactivation. Invest Ophthalmol Vis Sci 1993;34:2282-90.
7. Miller JK, Laycock KA, Umphress JA, Hook KK, Stuart PM, Pepose JS. A comparison of recurrent and primary herpes simplex keratitis in NIH inbred mice. Cornea 1996;15:497-504.
8. Berman PW, Vogt PE, Gregory T, Lasky LA, Kern ER. Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs. J Infect Dis 1988;157:897-902.
9. Shimeld C, Hill TJ, BIyth WA, Easty DL. Passive immunization protects the mouse eye from damage after herpes simplex virus infection by limiting spread of virus in the nervous system. J Gen Virol 1990;71: 681-7.
10. Morrison LA, Knipe DM. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol 1994;68:689-96.
11. Hill T. Ocular pathogenicity of herpes simplex virus. Curr Eye Res 1987; 6:1-7.
12. Eing BR, Kühn JE, Braun RW. Neutralizing activity of antibodies against the major herpes simplex virus type 1 glycoproteins. J Med Virol 1989; 27:59-65.
13. Yasukawa M, Zarling JM. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. J Immunol 1985;134:2679-82.
14. Pereira L, Klassen T, Baringer JR. Type-common and type-specific monoclonal antibody to herpes simplex virus type 1. Infect Immun 1980;29: 724-32.